

November 8, 2025

BSE Limited,
Department of Corporate Services,
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001

Scrip code: 542665

Debt Segment Code: 977028

Sub: Disclosure as per Regulation 52(7) and 52(7A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and as per SEBI Circular No. SEBI/HO/DDHS/DDHS-PoD-1/P/CIR/2024/48 dated May 21, 2024, as amended from time to time, with respect to statement of utilization of issue proceeds of Debt Securities for the quarter ended September 30, 2025.

Dear Sir/Madam,

In terms of regulations and circulars as mentioned in the captioned subject, we hereby confirm that there have been no deviations, in the use of proceeds of issue of Non- Convertible Debentures (NCDs) from the objects stated in the Key Information Document bearing reference no.: NCL/KID/2025-26/001 dated August 11, 2025 for the quarter ended September 30, 2025.

We hereby enclose a Statement of utilization of issue proceeds of above-mentioned NCDs issued by the Company for the quarter ended September 30, 2025 as **Annexure A** and the statement of NIL material deviation in the use of the proceeds of issue of the abovementioned NCDs issued by the Company from the objects stated in the relevant Key Information Document bearing reference no.: NCL/KID/2025-26/001 dated August 11, 2025 as **Annexure B**.

This information is also being uploaded on the Company's website at <https://neogenchem.com/announcements/>.

The same may please be taken on record.

**Thanking you,
For Neogen Chemicals Limited**

**Unnati Kanani
Company Secretary & Compliance Officer
Membership No: A35131**



NEOGEN[®]
CHEMICALS LTD.

Annexure A

Sr. No.	Particulars	Details
1	Name of the Issuer	Neogen Chemicals Limited
2	ISIN	INE136S07013
3	Mode of Fund Raising (Public issues/ Private placement)	Private placement
4	Type of instrument	Fully paid, secured, listed, rated, redeemable, rupee denominated, non-cumulative, non-convertible debentures
5	Date of raising funds	August 12, 2025
6	Report filed for the quarter	September 30, 2025
7	Amount Raised (in INR)	Rs. 200 Crores
8	Funds utilized (in INR)	Rs. 200 Crores utilised towards the original objects as per Key Information Document.
9	Any deviation (Yes/ No)	No
10	If 9 is Yes, then specify the purpose of for which the funds were utilized	Not applicable since there is no deviation.
11	Remarks, if any	N.A.



Annexure B
Statement of Deviation / Variation in utilisation of Issue Proceeds of Debt Securities for the quarter ended September 30, 2025

Name of Issuer	Neogen Chemicals Limited
ISIN	INE136S07013
Mode of Fund Raising (Public issues/ Private placement)	Private Placement
Type of instrument	20,000 Fully paid, secured, listed, rated, redeemable, rupee denominated, noncumulative, non-convertible debentures of face value of Rs. 1,00,000 each.
Date of Raising Funds	12-08-2025
Amount Raised (Rs. In crores)	200 crores
Report filed for Quarter ended	30-09-2025
Is there a Deviation / Variation in use of funds raised	No
Whether any approval is required to vary the objects of the issue stated in the prospectus/ offer document?	No
If yes, details of the approval so required?	Not Applicable
Date of approval	Not Applicable
Explanation for the deviation/ variation	Not Applicable
Comments of the audit committee after review	Nil
Comments of the auditors, if any	Nil
Objects for which funds have been raised and where there has been a deviation/ variation, in the following table	See table below

(Amount in Crores)


Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 30-09-2025	Amount of Deviation/Variation for the quarter according to applicable object (in Rs. crore and in %)	Remarks if any
-----------------	-------------------------	---------------------	-----------------------------	--------------------------------	--	----------------

Not Applicable

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed

	
Name of Signatory	Gopikrishnan Sarathy
Designation	Chief Financial Officer

